Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancerAndrew J. Gunderson, Kristina H. Young, Venkatesh Rajamanickam et al.|OncoImmunology|2021Cited by 187
Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromeGeoffrey L. Uy, John F. DiPersio, John E. Godwin et al.|Blood|2017Cited by 62
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor MicroenvironmentDavid A. Knorr, Jeffrey V. Ravetch, Lucas Blanchard et al.|Cancer Immunology Research|2023Cited by 32
Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.R. Bryan Bell, Andrew D. Weinberg, Mark W. Schuster et al.|Journal of Clinical Oncology|2018Cited by 27
Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 ImmunotherapiesMichael P. Rettig, Jan Davidson‐Moncada, John E. Godwin et al.|Blood|2017Cited by 12